The World Health Organization (WHO) announced today that it has temporarily suspended the rollout of the AstraZeneca COVID-19 vaccine in several countries following reports of blood clot concerns among some recipients. This decision was made as a precautionary measure while experts conduct a thorough review of the cases.
The suspension follows reports from several European countries, including Denmark, Norway, and Iceland, where individuals who received the AstraZeneca vaccine developed rare blood clotting disorders. These countries had earlier halted the use of the vaccine pending further investigations. In response, WHO has convened its Global Advisory Committee on Vaccine Safety to assess the data and determine whether there is any causal link between the vaccine and the reported blood clots.
Dr. Soumya Swaminathan, WHO’s Chief Scientist, stressed the importance of taking all reports of potential side effects seriously while maintaining confidence in the overall safety of vaccines. “At this stage, we are taking a cautious approach to ensure the safety of the vaccines we deploy globally. The AstraZeneca vaccine has been widely used with no significant safety concerns so far, but we need to investigate these cases carefully,” Dr. Swaminathan said during a press briefing.
The AstraZeneca/Oxford vaccine has been administered to millions of people worldwide as part of the global effort to combat the COVID-19 pandemic. WHO, along with the European Medicines Agency (EMA), has reiterated that the benefits of the vaccine outweigh the risks, but investigations into the reported cases of blood clotting are ongoing.
The temporary suspension of the vaccine has raised concerns in countries that are relying on the AstraZeneca vaccine as part of their mass vaccination campaigns, particularly in lower-income nations participating in the COVAX initiative. WHO has urged countries to remain calm and continue other aspects of their vaccination programs while awaiting further guidance.
Dr. Tedros Adhanom Ghebreyesus, WHO Director-General, expressed confidence that the situation will be resolved swiftly. “We understand the concern and the urgency of this situation, and we are working closely with our partners to ensure that the safety and efficacy of all COVID-19 vaccines are upheld. We expect to have more definitive information soon,” Dr. Tedros stated.
Armenian Dram
Ghana Cedi
Gambian Dalasi
Guinea Franc
Nigerian Naira
CFA Franc BEAC
